Year-end Sale % OFF 
Abstract
Cisplatin is a classic chemotherapeutic agent widely used to treat different types of cancers including ovarian, head and neck, testicular and uterine cervical carcinomas. However, cisplatin induces acute kidney injury by directly triggering an excessive inflammatory response, oxidative stress, and programmed cell death of renal tubular epithelial cells, all of which lead to high mortality rates in patients. In this study, we examined the protective effect of protocatechuic aldehyde (PA) in vitro in cisplatin-treated tubular epithelial cells and in vivo in cisplatin nephropathy. PA is a monomer of Traditional Chinese Medicine isolated from the root of S. miltiorrhiza (Lamiaceae). Results show that PA prevented cisplatin-induced decline of renal function and histological damage, which was confirmed by attenuation of KIM1 in both mRNA and protein levels. Moreover, PA reduced renal inflammation by suppressing oxidative stress and programmed cell death in response to cisplatin, which was further evidenced by in vitro data. Of note, PA suppressed NAPDH oxidases, including Nox2 and Nox4, in a dosage-dependent manner. Moreover, silencing Nox4, but not Nox2, removed the inhibitory effect of PA on cisplatin-induced renal injury, indicating that Nox4 may play a pivotal role in mediating the protective effect of PA in cisplatin-induced acute kidney injury. Collectively, our data indicate that PA blocks cisplatin-induced acute kidney injury by suppressing Nox-mediated oxidative stress and renal inflammation without compromising anti-tumor activity of cisplatin. These findings suggest that PA and its derivatives may serve as potential protective agents for cancer patients receiving cisplatin treatment.
Highlights
Cisplatin is widely used in the treatment of various cancers including ovarian, head and neck, testicular and uterine cervical carcinomas (Pabla and Dong, 2008; Sung et al, 2008)
Our results show that protocatechuic aldehyde (PA) suppressed activation of the RIP1/RIP3/MLKL axis, which is regarded as the key pathway mediating necroptosis
Nephrotoxicity leads to high mortality in cisplatin-treated patients with cancer, identification of preventive agents for cisplatin-induced AKI is needed for clinical treatments
Summary
Cisplatin is widely used in the treatment of various cancers including ovarian, head and neck, testicular and uterine cervical carcinomas (Pabla and Dong, 2008; Sung et al, 2008). Approximately 30% of patients experience a marked decline in renal function after a single dose injection of cisplatin (Sung et al, 2008) To this point it is important to prevent cisplatin-induced acute kidney injury, which is growing in clinical significance. Results presented here show that PA, isolated from the root of S. miltiorrhiza, is one of the most powerful protective TCM monomers It significantly suppressed cisplatin-induced injury of tubular epithelial cells and the inflammatory response. Results of MMT assay in three tumor cell lines demonstrated that treatment of PA didn’t alter the antitumor property of cisplatin These findings indicate that PA may be a potential therapeutic agent for preventing cisplatin-induced acute kidney injury
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
